English English Precision-engineered botanical actives, small-molecule peptides, and fermentation-derived powders manufactured under ISO 9001, ISO 22000, and HACCP validated standards to complement your high-tier formulation lines.
A rigorous examination of our proprietary biocatalytic enzyme-cascade synthesis route, designed to satisfy the ultra-low impurity limits demanded by Basel’s biopharmaceutical R&D laboratories and life sciences institutions.
Nicotinamide Mononucleotide (C11H15N2O8P, Molecular Weight: 334.22 g/mol, CAS Number: 1094-61-7) serves as the direct biochemical precursor to Nicotinamide Adenine Dinucleotide (NAD+). In clinical life science procurement across the Basel-Stadt and Basel-Landschaft cantons, chemical synthesis routes pose unacceptable liabilities due to chiral impurities (α-anomer contamination) and toxic residual halogenated solvents (such as dichloromethane and chloroform).
Our cGMP-aligned manufacturing facility employs an advanced two-stage, immobilized multi-enzyme catalytic cascade simulating endogenous eukaryotic salvage pathways:
Following enzymatic turnover, the aqueous reaction matrix undergoes continuous nano-filtration, vacuum ultrafiltration, low-temperature crystallization, and high-vacuum centrifugal freeze-drying, yielding an ultra-dense, free-flowing crystalline powder with minimal hygroscopic vulnerability.
| Test Parameter | Basel Quality Standard | Factory In-House Release Specification | Analytical Methodology |
|---|---|---|---|
| Chemical Purity (β-Anomer) | ≥99.0% | ≥99.85% (Typical Batch: 99.9%) | Reverse-Phase HPLC (Shimadzu Prominence) |
| Chiral Purity (α-NMN Impurity) | <0.5% | Not Detected (<0.05% LOQ) | Chiral Stationary Phase HPLC |
| Free Nicotinamide (NAM) Residue | <0.5% | ≤0.08% | HPLC-UV (254 nm) |
| Heavy Metals (Pb, As, Cd, Hg) | Total <5.0 ppm | Total <1.0 ppm (Pb <0.2, As <0.1, Cd <0.05, Hg <0.01) | ICP-MS (Inductively Coupled Plasma Mass) |
| Residual Organic Solvents | ICH Guideline Q3C Class 2/3 | Zero Organic Solvents (Aqueous Enzymatic Synthesis) | Headspace Gas Chromatography (GC-FID) |
| Bulk Density Profile | 0.30 – 0.70 g/mL | Custom Tuned: High Density (≥0.60 g/mL) for Direct Encapsulation | USP <616> Method I Tap Density Tester |
| Bacterial Endotoxins | <2.0 EU/mg | <0.20 EU/mg (Cleanroom Grade Formulation) | Kinetic Chromogenic LAL Assay |
| Stability Parameters (Zone II) | 24 Months Shelf Life | 36 Months Verified Stability (4°C – 25°C, Protected Packaging) | Accelerated & Real-Time ICH Q1A(R2) Protocols |
Basel stands as Europe’s undisputed epicenter of biopharmaceuticals, translational longevity research, and specialized contract manufacturing. Our export operations are engineered to meet the granular formulation and raw material specifications of Basel-based enterprises.
Academic laboratories, biotech spin-offs, and incubation centers situated in Basel’s technology parks (including Allschwil and St. Johann) investigate mitochondrial degradation, sirtuin activation (SIRT1, SIRT3, SIRT6), and DNA damage repair mediated by PARP-1 enzymes. Our pure β-NMN powder delivers batch-level chemical uniformity and certified zero cytotoxic solvent residues, ensuring reproducible in-vitro cellular assays and in-vivo pharmacokinetic modeling.
The contract manufacturing corridor surrounding the Rhine Valley demands raw powders with flawless mechanical properties. Low-grade NMN frequently exhibits irregular, needle-like morphology leading to electrostatic clustering, hopper bridging, and severe weight variation during high-speed capsule filling. Our specialized crystallization and mechanical milling produce spherical, granular β-NMN crystals with high tap density (≥0.60 g/mL), enabling smooth, lubricant-minimal rotary compression and high-volume encapsulation.
Private longevity institutes, medical spas, and preventative health practices throughout Basel, Zurich, and surrounding cantons formulate personalized anti-aging formulations and physician-dispensed nutraceuticals. In these therapeutic settings, patient trust depends entirely on contaminant-free certifications. We provide exhaustive toxicological profiling, pesticide screening (EU 396/2005 compliant), low bioburden assurance, and documented non-GMO origin on every delivered batch.
Basel’s prestige dermocosmetics sector actively explores NAD+ boosters to stimulate cutaneous collagen production, inhibit UV-induced photoaging, and reinforce skin epidermal barrier function. Our ultra-purified β-NMN is engineered with exceptional aqueous solubility and crystalline dissolution kinetics, facilitating seamless cold-process incorporation into topical liposomal serums, submicron emulsions, and transdermal patches without recrystallization or phase destabilization.
Modern preventative formulations in Switzerland rarely deploy NMN as a solitary active. Leading Basel brand holders design sophisticated multi-target longevity systems combining β-NMN with trans-resveratrol, fisetin, quercetin, spermidine, and Pyrroloquinoline Quinone (PQQ). Leveraging our in-house micro-blending systems, we manufacture custom homogeneous pre-blended bulk powders, drastically reducing handling errors and quality control overhead for Swiss formulators.
Because oral bioavailability of unmodified NMN is subject to first-pass gut degradation, innovative Swiss drug delivery developers utilize sublingual and fast-melt buccal delivery formats. Our crystalline powder exhibits controlled particle sizing (specifically milled to 80–100 mesh) that promotes rapid sublingual mucosal dissolution while providing optimal compressibility without capping or lamination during rotary tablet compaction.
Operating within the regulatory matrix overseen by Swissmedic and the Federal Food Safety and Veterinary Office (FSVO) requires foresight, uncompromising documentary compliance, and agile supply chain logistics.
The regulatory status of Nicotinamide Mononucleotide in Europe and Switzerland is transitioning toward rigorous pharmaceutical and specialized dietary classification. While in the United States NMN faces regulatory classification debates regarding clinical trial investigations (IND exclusion), the Swiss health ecosystem maintains an analytical, safety-first stance.
Procurement teams across Basel are proactively future-proofing their brands against impending regulatory thresholds by prioritizing:
Our export division closely monitors Swiss FSVO circulars and European Food Safety Authority (EFSA) guidance documents, ensuring every batch shipped into the Basel-Stadt territory is accompanied by an airtight, future-ready compliance dossier.
Detailed technical, regulatory, and logistics clarifications addressing the specific compliance requirements of Swiss procurement specialists and quality assurance teams.
Consistently bridging the gap between rigorous Chinese industrial-scale bio-manufacturing and the uncompromising precision benchmarks mandated by Swiss pharmaceutical buyers.
BKYULA Biotech operates modern bio-extraction, enzymatic synthesis, and drying workshops designed under strict cGMP principles. Our operations, equipment, and management workflows have been thoroughly verified onsite by SGS Group, giving European and Swiss procurement directors verified peace of mind prior to audit initiation.
Key enterprise operational differentiators include:
Physical plant facilities, employee capacities, and production integrity audited independently by SGS Group.
Full conformance to ISO 9001:2015, ISO 22000, HACCP, Kosher, Halal, and FAMI-QS industrial benchmarks.
Proprietary crystallization controls mean lot-to-lot purity deviations never exceed ±0.1% across multi-ton runs.
Reliable DDP and CIP door-to-door delivery handling into Basel, Zurich, and the wider Swiss biopharma corridor.
Whether you require pilot batch samples (100g – 1kg) for cell-line validation in Basel, customized high-density powder for rotary tableting, or a scheduled contract quotation for commercial-scale supply, our team is standing by to assist with full specifications and certificates.